Diminuição dos Níveis Séricos do Receptor Solúvel da Oncostatina M (sOSMR) e Glicoproteína 130 (sgp130) em Pacientes com Doença Arterial Coronariana

[1]  Deepak L. Bhatt,et al.  Diagnosis and Treatment of Acute Coronary Syndromes: A Review. , 2022, JAMA.

[2]  A. L. Ribeiro,et al.  Estatística Cardiovascular – Brasil 2021 , 2022, Arquivos brasileiros de cardiologia.

[3]  K. Aizawa,et al.  Oncostatin M is a novel biomarker for coronary artery disease – A possibility as a screening tool of silent myocardial ischemia for diabetes mellitus , 2021, International journal of cardiology. Heart & vasculature.

[4]  U. Laufs,et al.  Chronisches Koronarsyndrom , 2020, Der Internist.

[5]  Yan Li,et al.  Associations between the IL-6-neutralizing sIL-6R-sgp130 buffer system and coronary artery disease in postmenopausal women , 2020, Annals of translational medicine.

[6]  S. Vermeire,et al.  Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD) , 2019, Expert opinion on therapeutic targets.

[7]  A. Gomes,et al.  Ponceau S waste: Ponceau S staining for total protein normalization. , 2019, Analytical biochemistry.

[8]  M. Trojanowska,et al.  Oncostatin M and its role in fibrosis , 2018, Connective tissue research.

[9]  G. Pasterkamp,et al.  Inflammatory cytokine oncostatin M induces endothelial activation in macro- and microvascular endothelial cells and in APOE*3Leiden.CETP mice , 2018, PloS one.

[10]  A. Hegazy,et al.  The oncostatin M‐stromal cell axis in health and disease , 2018, Scandinavian journal of immunology.

[11]  H. Mariz,et al.  Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations. , 2018, Immunology letters.

[12]  B. Gersh,et al.  Coronary Artery Disease in Patients ≥80 Years of Age. , 2018, Journal of the American College of Cardiology.

[13]  V. Rangnekar,et al.  Neoadjuvant administration of hydroxychloroquine in a phase 1 clinical trial induced plasma Par-4 levels and apoptosis in diverse tumors , 2018, Genes & cancer.

[14]  E. Samoilova,et al.  Soluble glycoprotein 130 is inversely related to severity of coronary atherosclerosis , 2018, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[15]  D. Celermajer,et al.  The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. , 2017, Atherosclerosis.

[16]  Yan Li,et al.  Circulating levels of sgp130 and sex hormones in male patients with coronary atherosclerotic disease. , 2017, Atherosclerosis.

[17]  M. Eghbali,et al.  The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy , 2017, Biology of Sex Differences.

[18]  Haichang Wang,et al.  OSM mitigates post-infarction cardiac remodeling and dysfunction by up-regulating autophagy through Mst1 suppression. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[19]  Hongliang Li,et al.  Oncostatin M receptor β deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages , 2017, Journal of Lipid Research.

[20]  Morten Wang Fagerland,et al.  Circulating Levels of IL‐6 Receptor and gp130 and Long‐Term Clinical Outcomes in ST‐Elevation Myocardial Infarction , 2016, Journal of the American Heart Association.

[21]  H. Hermanns.  Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. , 2015, Cytokine & growth factor reviews.

[22]  U. de Faire,et al.  Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction. , 2015, Atherosclerosis.

[23]  N. Coleman,et al.  Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma , 2014, The Journal of pathology.

[24]  Xiaotao Li,et al.  Relationship between serum oncostatin M levels and degree of coronary stenosis in patients with coronary artery disease. , 2014, Clinical laboratory.

[25]  M. Sikkel,et al.  Coronary artery disease and age: beyond atherosclerosis , 2013, The Journal of physiology.

[26]  S. Rose-John,et al.  Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice. , 2013, Arthritis and rheumatism.

[27]  J. McMurray,et al.  Soluble Glycoprotein 130 Predicts Fatal Outcomes in Chronic Heart Failure: Analysis From the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) , 2013, Circulation. Heart failure.

[28]  T. Walther,et al.  Therapeutic targeting of the oncostatin M receptor-β prevents inflammatory heart failure , 2013, Basic Research in Cardiology.

[29]  S. Kostin,et al.  Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling. , 2011, Cell stem cell.

[30]  A. Saraya,et al.  Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma , 2011, Cellular Oncology.

[31]  Y. Appelman,et al.  Gender differences in coronary heart disease , 2010, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[32]  S. Chevalier,et al.  Molecular and Functional Characterization of a Soluble Form of Oncostatin M/Interleukin-31 Shared Receptor*> , 2006, Journal of Biological Chemistry.

[33]  C. Härtel,et al.  Cytokine responses correlate differentially with age in infancy and early childhood , 2005, Clinical and experimental immunology.

[34]  S. Rose-John,et al.  Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130 , 2003, The Journal of Immunology.

[35]  K. Matthews,et al.  Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. , 2003, Journal of the American College of Cardiology.

[36]  Stephen K. Smith,et al.  Soluble gp130 is up-regulated in the implantation window and shows altered secretion in patients with primary unexplained infertility. , 2002, The Journal of clinical endocrinology and metabolism.

[37]  A. Wahl,et al.  Oncostatin M in the anti-inflammatory response , 2001, Annals of the rheumatic diseases.

[38]  B. Klein,et al.  Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin‐6 signal transducer gp130 1 , 1997, FEBS letters.